6ix — Find Your Next Investment

Discover investor relations events, company profiles, and investment opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
6m ago	Mphasis acquires Theory and Practice Business Intelligence Inc., strengthening its 'Decisioning Intelligence' capabilities
6m ago	S&P upgrades SiriusPoint’s Insurance Subsidiaries to ‘A’ based on consistent robust earnings and strength of capital position
6m ago	Omnicom Expands Adobe Partnership to Drive Industry-Specific AI-Powered Marketing Transformation
7m ago	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
7m ago	Schlumberger Foundation Celebrates Its 1,000th Faculty for the Future Grant

About

Corcept Therapeutics Incorporated (NASDAQ:CORT) — investor relations, events, news, and company updates on 6ix.

Latest News

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Financials

Revenue

$761.41 M

Market Cap

$4.52 B

P/E Ratio

51.82

EPS

0.82

Community Chat

Ask AI